Cogent Biosciences, Inc. has submitted a New Drug Application to the U.S. Food and Drug Administration for bezuclastinib in advanced systemic mastocytosis, marking the company’s third FDA submission for the selective KIT mutant inhibitor in six months. The application is supported by positive data from the APEX pivotal trial, where bezuclastinib demonstrated objective response rates of 65% per modified International Working Group criteria and 81% per pure pathological response criteria in patients with advanced systemic mastocytosis. The regulatory milestone is clinically important because advanced systemic mastocytosis remains a rare, aggressive mast cell disease driven largely by KIT mutations, and treatment decisions depend heavily on balancing deep disease control with long-term tolerability.
Why does Cogent’s bezuclastinib NDA matter for advanced systemic mastocytosis?
Cogent’s NDA submission matters because advanced systemic mastocytosis is a serious and potentially life-threatening disease with limited treatment options and substantial clinical complexity. The condition involves abnormal accumulation and activation of mast cells, often driven by the KIT D816V mutation. Patients may experience organ damage, cytopenias, liver involvement, bone marrow dysfunction, constitutional symptoms and complications from mast cell mediator release.
Bezuclastinib is designed as a highly selective tyrosine kinase inhibitor targeting KIT D816V and other KIT exon 17 mutations. That selectivity is central to Cogent’s development strategy because many patients with advanced systemic mastocytosis need sustained KIT inhibition, but long-term treatment can be limited by off-target toxicity, tolerability issues and dose modification. A therapy that can deliver deep disease control while maintaining manageable safety could become clinically meaningful if approved.
The NDA is also important because it expands the regulatory footprint for bezuclastinib. Cogent has now submitted three bezuclastinib applications in six months, including submissions tied to non-advanced systemic mastocytosis and gastrointestinal stromal tumors. That pace suggests the company is attempting to build a broader rare disease and precision oncology franchise around the same core molecule.
The advanced systemic mastocytosis submission does not guarantee approval. FDA review will need to evaluate response durability, safety, patient population, trial design, manufacturing, labeling and the totality of evidence from APEX. Still, the application moves bezuclastinib into a defined regulatory review process for a high-need hematologic disease.
What did the APEX pivotal trial show about bezuclastinib response rates?
The APEX pivotal trial provides the clinical basis for the advanced systemic mastocytosis NDA. As of the March 31, 2026 data cutoff, 81 patients with advanced systemic mastocytosis had been treated with 150 mg of bezuclastinib. The trial included patients with systemic mastocytosis with an associated hematologic neoplasm, aggressive systemic mastocytosis and mast cell leukemia, reflecting the heterogeneity of advanced disease.
The primary response assessment under modified International Working Group and European Competence Network on Mastocytosis criteria showed a 65% objective response rate among 68 evaluable patients. Importantly, 57% of patients achieved complete remission, complete remission with partial hematologic recovery or partial remission as their best response. These categories matter because they suggest not only symptomatic improvement, but deeper disease modification across clinically meaningful response levels.
Cogent also reported an 81% objective response rate under pure pathological response criteria among 81 patients. Pure pathological response is clinically relevant in advanced systemic mastocytosis because it focuses on bone marrow and disease pathology changes, which may reflect the underlying mast cell burden more directly than symptom improvement alone.
The response data are encouraging, but clinicians will still want to interpret them alongside durability, safety and disease subtype results. Advanced systemic mastocytosis includes several biologically and clinically different patient groups. How bezuclastinib performs across those subgroups will be important for treatment selection if the therapy reaches market.
Why do disease marker reductions strengthen the bezuclastinib evidence package?
Disease marker reductions strengthen the evidence package because advanced systemic mastocytosis is driven by abnormal mast cell proliferation and KIT-mutated disease biology. Cogent reported that bezuclastinib achieved clinically significant reductions across objective disease markers, including serum tryptase, bone marrow mast cells and KIT D816V variant allele frequency.
The company reported that 89% of evaluable patients had at least a 50% reduction in serum tryptase. Serum tryptase is commonly used as a marker of mast cell burden and disease activity, so substantial reductions can support the interpretation that treatment is affecting the underlying disease process. Cogent also reported that 89% of patients had at least a 50% reduction in bone marrow mast cells or clearance of aggregates, which points to improvement in pathological disease burden.
The KIT D816V variant allele frequency result may be especially important. Cogent reported that 91% of evaluable patients achieved at least a 50% reduction in KIT D816V variant allele frequency, and approximately one-third reached undetectable levels. This suggests that bezuclastinib may be affecting the mutant clone that drives disease biology in many patients.
These biomarker findings do not replace clinical outcomes, but they add biological coherence to the response data. For a targeted therapy, regulators and clinicians often look for alignment among mechanism, biomarkers, pathology and patient outcomes. The APEX data appear to support that alignment, which strengthens the rationale for FDA review.
Could bezuclastinib’s 12-month survival profile strengthen its AdvSM approval case?
Durability is important because advanced systemic mastocytosis often requires chronic treatment. A therapy that produces early responses but loses activity quickly would have limited clinical value. Cogent reported that bezuclastinib demonstrated durable clinical activity, with a 12-month progression-free survival rate of 79% and a 12-month overall survival rate of 87%. Median progression-free survival and overall survival were immature at the data cutoff.
Those figures are clinically meaningful because advanced systemic mastocytosis can progress aggressively, especially in patients with mast cell leukemia or associated hematologic neoplasms. A 12-month disease control profile helps clinicians evaluate whether bezuclastinib could support longer-term management rather than only short-term response.
Cogent also reported that effects were observed as early as eight weeks, including high pure pathological response rates, improvement or normalization of bone marrow mast cell distribution, broader bone marrow improvements and normalization of serum tryptase in a majority of patients. Early response may matter in advanced disease because patients can present with substantial symptom burden and organ involvement.
The durability picture will become clearer with longer follow-up. Because median progression-free survival and overall survival were not mature, clinicians will watch future data releases for extended outcomes, resistance patterns and whether response depth translates into sustained clinical benefit across disease subtypes.
What does the safety profile suggest about bezuclastinib’s clinical utility?
Cogent reported that bezuclastinib was well tolerated as of the APEX data cutoff, with infrequent need for dose reduction or discontinuation due to treatment-related adverse events. That tolerability profile is important because advanced systemic mastocytosis patients may need ongoing treatment, and many may have overlapping hematologic, hepatic or systemic complications.
The most frequent treatment-related adverse events reported with bezuclastinib were hair color change, neutropenia, altered taste, thrombocytopenia and ALT or AST elevations. Most transaminase elevations were described as low grade, asymptomatic and reversible. Among two patients who experienced Grade 3 transaminase elevation, one discontinued treatment and one remained on therapy after dose reduction.
The safety profile will be a key part of FDA review because response rates alone are not enough in rare hematologic diseases. Physicians need therapies that can be administered long enough to maintain disease control without causing unacceptable toxicity or frequent discontinuation. A selective KIT inhibitor must prove that its selectivity translates into a practical benefit-risk profile in real patients.
If approved, the final label will be important. Dose modification guidance, monitoring requirements, liver enzyme management, blood count monitoring and patient selection could all influence adoption. A favorable label could help bezuclastinib compete more effectively, while restrictive monitoring or safety warnings could affect uptake.
How does the AdvSM NDA fit into Cogent’s broader bezuclastinib strategy?
The advanced systemic mastocytosis NDA is part of a broader strategy to develop bezuclastinib across KIT-driven diseases. Cogent has positioned the drug as a selective inhibitor for KIT D816V and other KIT exon 17 mutations, which are relevant in systemic mastocytosis and certain gastrointestinal stromal tumors. The company’s PEAK and SUMMIT reviews are ongoing, and Cogent expects potential approvals in the fourth quarter of 2026.
This is strategically significant because bezuclastinib could become more than a single-indication therapy. If the FDA approves multiple submissions, Cogent may be able to build a franchise across advanced systemic mastocytosis, non-advanced systemic mastocytosis and GIST. That would give clinicians a targeted therapy with potential relevance across different KIT-mutant patient populations.
The advanced systemic mastocytosis indication is particularly important because it represents a more aggressive disease setting. Success here would support the argument that selective KIT inhibition can deliver meaningful benefit even in high-risk disease. It could also strengthen confidence in the molecule’s broader clinical utility.
The challenge is that each indication has different clinical, regulatory and commercial dynamics. Systemic mastocytosis and GIST involve different treating specialists, disease monitoring needs and competitive landscapes. Cogent will need to manage labeling, education, access and sequencing carefully if bezuclastinib receives approvals across multiple settings.
What should clinicians watch as the FDA reviews bezuclastinib in AdvSM?
Clinicians should watch whether the FDA accepts the APEX response data as sufficient to support approval in advanced systemic mastocytosis. The primary endpoint response rate is strong, but regulatory review will assess response durability, disease subtype representation, safety, dose management and consistency across objective disease markers.
Additional follow-up from APEX will be important. Longer progression-free survival and overall survival data could help clarify how durable bezuclastinib benefit is in advanced disease. Clinicians will also want more information on outcomes across systemic mastocytosis with associated hematologic neoplasm, aggressive systemic mastocytosis and mast cell leukemia, since these groups can differ substantially in prognosis and treatment needs.
Safety monitoring will also be central. Blood count abnormalities, taste changes, liver enzyme elevations and other treatment-related events will need to be understood in the context of long-term use. If the therapy is approved, practical management guidance will help determine how easily clinicians can integrate bezuclastinib into care.
The broader question is whether bezuclastinib can improve the treatment standard by offering deep disease control with fewer severe tolerability challenges than available approaches. Cogent’s NDA brings that question to the FDA. The review outcome will determine whether bezuclastinib becomes a new option for patients with advanced systemic mastocytosis.
